Comparative Pharmacology
Head-to-head clinical analysis: ESTRATAB versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRATAB versus STILBESTROL.
ESTRATAB vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy. Estrone sulfate and other conjugated estrogens bind to estrogen receptors, activating gene transcription and producing estrogenic effects on various target tissues including the uterus, breast, bone, and cardiovascular system.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
1 tablet (estrogens 0.625 mg / methyltestosterone 1.25 mg) orally once daily cyclic (3 weeks on, 1 week off) for menopausal symptoms; adjust based on response.
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Estrone sulfate has a terminal half-life of approximately 10-16 hours; estradiol has a shorter half-life of 1-2 hours. Due to conversion to estrone and enterohepatic cycling, clinical effects persist beyond plasma levels.
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Metabolites are excreted primarily in urine as glucuronide and sulfate conjugates (~60-80%), with ~10-20% excreted in feces via bile. Less than 5% is excreted unchanged.
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."